CJC Peptide (CJC-1295): What It Is, How It Works, and What the Evidence Shows

CJC peptide usually means CJC-1295, a synthetic growth hormone-releasing hormone (GHRH) analog that signals the pituitary gland to release growth hormone and raise IGF-1. It comes as CJC-1295 with DAC, a longer-acting form, and CJC-1295 without DAC, also called Modified GRF 1-29. CJC-1295 is not FDA-approved for any indication. [1]

What is the CJC peptide?

CJC-1295 is a lab-made version of growth hormone-releasing hormone, or GHRH. GHRH is a natural signal from the brain that tells the pituitary gland to release growth hormone in pulses. Early studies found that CJC-1295 can raise growth hormone and IGF-1, but these hormone changes do not prove reliable body-composition, sleep, recovery, or longevity outcomes. Side effects and monitoring still matter. [1][2]

CJC-1295 is often grouped with growth hormone secretagogues. A secretagogue is a substance that helps the body release a hormone. CJC-1295 is different from human growth hormone, also called HGH or somatropin, which is the hormone itself and is FDA-approved only for specific medical conditions. [4]

CJC-1295 with DAC vs. CJC-1295 without DAC (Modified GRF 1-29)

CJC-1295 with DAC, also called DAC:GRF, includes a drug-affinity complex that helps it bind to albumin in the blood. In Teichman et al. (2006), CJC-1295 with DAC had a reported half-life of about 5.8–8.1 days after study-administered subcutaneous doses. Longer activity may mean longer exposure if side effects occur, so clinicians consider risks before use. [1]

CJC-1295 without DAC is commonly called Modified GRF 1-29. It is shorter acting and closer to the natural pulse pattern of GHRH. There are fewer high-quality clinical outcome studies for common wellness goals, and CJC-1295 without DAC is not FDA-approved for any indication. [1][2]

How CJC-1295 differs from synthetic HGH

CJC-1295 signals the pituitary gland to release growth hormone. HGH, or somatropin, adds recombinant growth hormone directly. Somatropin labels warn about glucose intolerance, fluid retention, intracranial hypertension, active cancer concerns, and use restrictions during acute critical illness; clinicians often consider similar pathway risks when evaluating growth hormone secretagogues. [4]

How does CJC-1295 work in the body?

CJC-1295 works through the GHRH receptor in the pituitary gland. The pituitary then releases growth hormone, which can raise IGF-1, a liver-made signal involved in growth, tissue repair, and metabolism. In early research, hormone levels changed within days, but side effects and long-term safety remain important. [1][2]

GHRH signaling and the pituitary gland

The pituitary gland normally releases growth hormone in pulses, especially during sleep. With aging, average growth hormone and IGF-1 activity tends to decline, a pattern sometimes called somatopause. Researchers have studied GHRH-related compounds to understand this pathway, but that does not prove that CJC-1295 extends lifespan or improves healthspan. [5]

Effects on growth hormone and IGF-1 levels

Human studies of CJC-1295 show increases in growth hormone and IGF-1. In Teichman et al. (2006), healthy adults received single subcutaneous CJC-1295 doses of 30, 60, 125, or 250 μg/kg, and investigators reported dose-related increases in growth hormone and IGF-1; CJC-1295 is not FDA-approved for this or any other use. Higher IGF-1 is the intended biological signal, but it can also be a safety reason for lab monitoring. [1]

What are people using CJC-1295 for?

CJC-1295 is being studied and discussed in some clinical settings for goals tied to the growth hormone pathway, such as body composition, recovery, sleep quality, and healthy-aging plans. It is not FDA-approved for these uses. Evidence is stronger for raising growth hormone and IGF-1 than for proving patient-centered results. Side effects and contraindications must be considered in the same decision. [1][2][4]

Body composition, recovery, and sleep

People often ask about CJC-1295 for lean mass, fat loss, exercise recovery, or sleep. These goals are biologically plausible because growth hormone and IGF-1 affect metabolism and tissue repair, but direct trials proving reliable outcomes in generally healthy adults are limited. Possible downsides include swelling, numbness or tingling, joint discomfort, headache, injection-site reactions, and glucose changes. [1][4][8]

Longevity and healthy aging goals

CJC-1295 is sometimes discussed in longevity medicine because growth hormone signaling changes with age. Still, changing a hormone marker is not the same as proving longer life or better healthspan. Growth-hormone-pathway therapies may carry risks, so a clinician should review cancer history, sleep apnea, blood sugar, edema, and baseline IGF-1 before considering use. [5][8]

What the clinical evidence actually shows

The clearest evidence is that CJC-1295 can raise growth hormone and IGF-1 in early-phase studies. The evidence is less clear for how much a person will feel, sleep, recover, or change body composition. Individual results vary, and any possible benefit must be balanced with side effects, contraindications, and the fact that CJC-1295 is not FDA-approved. [1][2][4]

Why is CJC-1295 often stacked with ipamorelin?

CJC-1295 and ipamorelin are commonly combined in clinical and research practice because they act on different growth hormone signals. CJC-1295 is a GHRH analog, while ipamorelin is a growth hormone secretagogue that acts at the ghrelin receptor, also called GHS-R1a. This combination is not FDA-approved, and combination-specific safety trials are limited. [9]

GHRH analog + ghrelin receptor agonist

The rationale is that a GHRH analog supports one side of pituitary signaling, while a ghrelin-receptor agonist supports another. In theory, this may increase growth hormone pulse signaling more than either pathway alone. The safety caveat is overlapping effects, including fluid retention symptoms, headache, appetite changes, glucose changes, and elevated IGF-1. [4][9]

Comparison of CJC-1295 and ipamorelin

What are the side effects and risks of CJC-1295?

CJC-1295 side effects reported or considered in growth-hormone-pathway treatment include injection-site reactions, flushing, headache, tiredness, water retention, joint discomfort, numbness or tingling, and changes in blood sugar. Possible benefits, such as higher growth hormone or IGF-1, should never be viewed apart from these risks. [1][3][4]

Common reported side effects

• Injection-site redness, itching, swelling, or discomfort. [1]
• Headache, flushing, dizziness, or tiredness. [1]
• Fluid retention symptoms, such as swelling, joint aches, or tingling. [3][4]
• Possible changes in glucose handling, especially in people with diabetes risk. [3][4]
• Higher IGF-1 levels, which may need lab monitoring. [1][8]

Concerns from the discontinued phase II trial

A phase II study of CJC-1295 in HIV-associated lipodystrophy was terminated, and public trial records note a participant death. Public records do not prove that CJC-1295 caused the death, but the event is one reason this peptide deserves careful medical review rather than casual use. [10]

Who should avoid CJC peptide therapy

People with active cancer, unexplained masses, severe untreated sleep apnea, uncontrolled diabetes, severe acute illness, pregnancy, breastfeeding, or a history that makes IGF-1 elevation risky may not be candidates. These cautions are based in part on known risks of growth hormone pathway drugs and FDA-approved related products. [3][4][8]

How is CJC-1295 dosed and administered?

CJC-1295 is usually discussed as a subcutaneous injection, meaning a small injection under the skin. This article does not provide dosing instructions. Published studies used specific research doses under protocol oversight, and CJC-1295 is not FDA-approved for any use described here. [1][10]

Subcutaneous injection basics

In Teichman et al. (2006), healthy adults received CJC-1295 by subcutaneous injection at study-assigned doses, including 30, 60, 125, and 250 μg/kg in the single-dose phase; this was a research protocol, not patient dosing guidance, and CJC-1295 is not FDA-approved. A licensed clinician or pharmacist should teach storage, injection technique, needle safety, and what to do for adverse reactions if any injectable medication is prescribed. [1][6]

Dosing frequency studied for DAC vs. no-DAC forms

CJC-1295 with DAC is longer acting than Modified GRF 1-29. In Teichman et al. (2006), investigators reported prolonged growth hormone and IGF-1 effects after single subcutaneous CJC-1295 doses and described a half-life of about 5.8–8.1 days; CJC-1295 remains not FDA-approved for any indication. Shorter-acting Modified GRF 1-29 is discussed differently in practice, but high-quality outcome data are limited. [1][2]

Monitoring and follow-up labs

Clinicians may consider IGF-1, fasting glucose or A1c, lipids, weight, blood pressure, sleep apnea symptoms, edema, and side effects during follow-up. Monitoring is important because a rise in IGF-1 may be the intended signal, but excessive or unsafe pathway activation can create problems. [1][3][8]

Is CJC-1295 FDA-approved or legal?

CJC-1295 is not FDA-approved for any indication. That means the FDA has not approved a CJC-1295 drug product as safe and effective for body composition, recovery, sleep, longevity, hormone optimization, or any other use. Tesamorelin, sold as Egrifta, is a different GHRH analog that is FDA-approved for reducing excess abdominal fat in adults with HIV and lipodystrophy. [3]

Regulatory status and 503A compounding context

Compounded CJC-1295 via a 503A pharmacy may be discussed by licensed clinicians when allowed by law and when a patient-specific prescription is appropriate. A 503A pharmacy compounds medications for individual patients under state and federal rules. Compounded products are not FDA-approved, even when prepared by a licensed pharmacy. [6]

FDA bulk substances list considerations

Regulatory status of compounded peptides is evolving. Some peptides are currently under FDA review after FDA’s April 15–16, 2026 reclassification announcement, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026; FDA materials and public dockets should be checked for the latest status before any access decision. [7]

How can someone get CJC-1295 through a licensed provider?

CJC-1295 should start with a clinical evaluation, not a shopping cart. A licensed clinician can review goals, medical history, medications, cancer and diabetes risk, sleep apnea symptoms, baseline labs, and whether a non-approved compounded peptide is appropriate. Access is not guaranteed. [6][8]

Clinical evaluation and eligibility

A clinician may ask why you are interested in CJC-1295, what you have already tried, and whether safer or FDA-approved options fit the goal better. For example, the FDA-approved tesamorelin label describes 2 mg injected subcutaneously once daily for its specific HIV-related lipodystrophy indication; that label dose does not apply to CJC-1295, which is not FDA-approved. Any possible benefit should be weighed against side effects, contraindications, and monitoring needs. [3][8]

Working with a telehealth provider

Telehealth can be one route for education and clinician review when state law allows it. Chia is one option among licensed telehealth providers that can evaluate patients for compounded GLP-1 medications and longevity peptides through US 503A pharmacy partners when clinically appropriate, with attention to product quality, lab monitoring, and safety review. [6]

What peptides stack well with CJC-1295?

CJC-1295 stacks are commonly combined in clinical and research practice, but they are not FDA-approved protocols. There are limited combination-specific trials, so safety depends on clinician oversight, lab monitoring, and stopping if risks outweigh possible benefits. No combined dosing numbers are provided here. [6][8]

CJC-1295 + ipamorelin

The mechanistic rationale is that CJC-1295 supports the GHRH receptor while ipamorelin supports the ghrelin receptor, giving two signals to the growth hormone axis. The safety caveat is overlapping growth-hormone-pathway effects, including fluid retention symptoms, glucose changes, headache, appetite changes, and elevated IGF-1. [4][9]

CJC-1295 + sermorelin

Sermorelin is another GHRH-related peptide, so pairing it with CJC-1295 is usually redundant rather than clearly complementary. The safety caveat is that combining similar pathway signals may raise exposure without proven extra benefit, so clinicians often avoid unnecessary overlap. [8][11]

CJC-1295 + tesamorelin

Tesamorelin is an FDA-approved GHRH analog for a specific HIV lipodystrophy indication, not a general wellness peptide. Combining it with CJC-1295 is not an FDA-approved use and may increase growth-hormone-pathway risks, including glucose intolerance, fluid retention, and IGF-1 elevation. [3][8]

Keep reading

Longevity Peptides

Sermorelin: How It Works, Benefits, and Risks

Peptides

Tesamorelin and Ipamorelin: How the Peptide Combo Works

Longevity Peptides

CJC-1295 and Ipamorelin Dosage: What Patients Should Know